Amyloid-β (Aβ), a major component of senile plaques, is generated via the proteolysis of amyloid-β protein precursor (AβPP). This cleavage also produces AβPP fragment-derived oligomers which can be highly neurotoxic. AβPP metabolism/processing is affected by many factors, one of which is oxidative stress (OS). Associated with aging, OS is an important risk factor for Alzheimer’s disease. In addition, the protein degradation systems, especially those involving cathepsins, are impaired in aging brains. Moreover, cathepsin B (CTSB) is a cysteine protease with potentially specific roles in AβPP proteolysis (β-secretase activity) and Aβ clearance (Aβ degradative activity). The present work examines the effect of OS and the involvement of CTSB in amyloid oligomer formation. The xanthine/xanthine oxidase (X-XOD) free radical generating system induced the partial inhibition of CTSB activity, which was accompanied by an increase in large amyloid oligomers. These were located throughout the cytosol and in endo-lysosomal vesicles. Cells treated with the CTSB inhibitor CA-074Me also showed increased amyloid oligomer levels, whereas those subjected to OS in the presence of the inhibitor showed no such increase. However, CTSB inhibition clearly modulated the AβPP metabolism/processing induced by X-XOD, as revealed by the increase in intracellular AβPP and secreted α-secretase-cleaved soluble AβPP. The present results suggest that CTSB participates in the changes of amyloid oligomer induced by mild OS.
BlennowK, de LeonMJ, ZetterbergH (2006) Alzheimer’s disease. Lancet368, 387–403.
2.
GlennerGG, WongCW, QuarantaV, EanesED (1984) The amyloid deposits in Alzheimer’s disease: their nature and pathogenesis. Appl Pathol2, 357–369.
3.
HaassC, KaetherC, ThinakaranG, SisodiaS (2012) Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med2, a006270.
4.
JanA, GokceO, Luthi-CarterR, LashuelHA (2008) The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity. J Biol Chem283, 28176–28189.
5.
ShahP, LalN, LeungE, TraulDE, Gonzalo-RuizA, GeulaC (2010) Neuronal and axonal loss are selectively linked to fibrillar amyloid-beta within plaques of the aged primate cerebral cortex. Am J Pathol177, 325–333.
6.
McLeanCA, ChernyRA, FraserFW, FullerSJ, SmithMJ, BeyreutherK, BushAI, MastersCL (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann Neurol46, 860–866.
7.
Baker-NighA, VahediS, DavisEG, WeintraubS, BigioEH, KleinWL, GeulaC (2015) Neuronal amyloid-beta accumulation within cholinergic basal forebrain in ageing and Alzheimer’s disease. Brain138, 1722–1737.
8.
WoltjerRL, NghiemW, MaezawaI, MilatovicD, VaisarT, MontineKS, MontineTJ (2005) Role of glutathione in intracellular amyloid-alpha precursor protein/carboxy-terminal fragment aggregation and associated cytotoxicity. J Neurochem93, 1047–1056.
9.
ChengF, CappaiR, CiccotostoGD, SvenssonG, MulthaupG, FranssonLA, ManiK (2011) Suppression of amyloid beta A11 antibody immunoreactivity by vitamin C: possible role of heparan sulfate oligosaccharides derived from glypican-1 by ascorbate-induced, nitric oxide (NO)-catalyzed degradation. J Biol Chem286, 27559–27572.
10.
NixonRA, CataldoAM (1995) The endosomal-lysosomal system of neurons: new roles. Trends Neurosci18, 489–496.
11.
VassarR, BennettBD, Babu-KhanS, KahnS, MendiazEA, DenisP, TeplowDB, RossS, AmaranteP, LoeloffR, LuoY, FisherS, FullerJ, EdensonS, LileJ, JarosinskiMA, BiereAL, CurranE, BurgessT, LouisJC, CollinsF, Tre-anorJ, RogersG, CitronM (1999) Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science286, 735–741.
12.
SoldanoA, HassanBA (2014) Beyond pathology: APP, brain development and Alzheimer’s disease. Curr Opin Neurobiol27, 61–67.
13.
HookV, ToneffT, BogyoM, GreenbaumD, MedzihradszkyKF, NeveuJ, LaneW, HookG, ReisineT (2005) Inhibition of cathepsin B reduces beta-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate beta-secretase of Alzheimer’s disease. Biol Chem386, 931–940.
14.
Mueller-SteinerS, ZhouY, AraiH, RobersonED, SunB, ChenJ, WangX, YuG, EspositoL, MuckeL, GanL (2006) Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer’s disease. Neuron51, 703–714.
15.
CataldoAM, BarnettJL, PieroniC, NixonRA (1997) Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer’s disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. J Neurosci17, 6142–6151.
16.
NunomuraA, PerryG, AlievG, HiraiK, TakedaA, BalrajEK, JonesPK, GhanbariH, WatayaT, ShimohamaS, ChibaS, AtwoodCS, PetersenRB, SmithMA (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol60, 759–767.
17.
BondaDJ, WangX, PerryG, NunomuraA, TabatonM, ZhuX, SmithMA (2010) Oxidative stress in Alzheimer disease: a possibility for prevention. Neuropharmacology59, 290–294.
18.
NunomuraA, MoreiraPI, CastellaniRJ, LeeHG, ZhuX, SmithMA, PerryG (2012) Oxidative damage to RNA in aging and neurodegenerative disorders. Neurotox Res22, 231–248.
19.
Martinez-VicenteM, SovakG, CuervoAM (2005) Protein degradation and aging. Exp Gerontol40, 622–633.
20.
YamashimaT (2013) Reconsider Alzheimer’s disease by the 'calpain-cathepsin hypothesis'-a perspective review. Prog Neurobiol105, 1–23.
21.
RecueroM, VicenteMC, Martinez-GarciaA, RamosMC, Carmona-SaezP, SastreI, AldudoJ, VilellaE, FrankA, BullidoMJ, ValdiviesoF (2009) A free radical-generating system induces the cholesterol biosynthesis pathway: a role in Alzheimer’s disease. Aging Cell8, 128–139.
22.
RecueroM, MunozT, AldudoJ, SubiasM, BullidoMJ, ValdiviesoF (2010) A free radical-generating system regulates APP metabolism/processing. FEBS Lett584, 4611–4618.
23.
RecueroM, MuniveVA, SastreI, AldudoJ, ValdiviesoF, BullidoMJ (2013) A free radical-generating system regulates AbetaPP metabolism/processing: involvement of the ubiquitin/proteasome and autophagy/lysosome pathways. J Alzheimers Dis34, 637–647.
24.
RubinszteinDC (2006) The roles of intracellular proteindegradation pathways in neurodegeneration. Nature443, 780–786.
25.
DouglasPM, DillinA (2010) Protein homeostasis and aging in neurodegeneration. J Cell Biol190, 719–729.
26.
HansenMB, NielsenSE, BergK (1989) Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods119, 203–210.
27.
PorterK, NallathambiJ, LinY, LitonPB (2013) Lysosomal basification and decreased autophagic flux in oxidatively stressed trabecular meshwork cells: implications for glaucoma pathogenesis. Autophagy9, 581–594.
28.
AvrahamiL, FarfaraD, Shaham-KolM, VassarR, FrenkelD, Eldar-FinkelmanH (2013) Inhibition of glycogen syn-thase kinase-3 ameliorates beta-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies. J Biol Chem288, 1295–1306.
29.
IllyC, QuraishiO, WangJ, PurisimaE, VernetT, MortJS (1997) Role of the occluding loop in cathepsin B activity. J Biol Chem272, 1197–1202.
KayedR, HeadE, ThompsonJL, McIntireTM, MiltonSC, CotmanCW, GlabeCG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science300, 486–489.
32.
KayedR, HeadE, SarsozaF, SaingT, CotmanCW, NeculaM, MargolL, WuJ, BreydoL, ThompsonJL, RasoolS, GurloT, ButlerP, GlabeCG (2007) Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener2, 18.
33.
LesneS, KohMT, KotilinekL, KayedR, GlabeCG, YangA, GallagherM, AsheKH (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature440, 352–357.
34.
AndrewRJ, KellettKA, ThinakaranG, HooperNM (2016) A Greek tragedy: the growing complexity of Alzheimer amyloid precursor protein proteolysis. J Biol Chem291, 19235–19244.
35.
ViolaKL, KleinWL (2015) Amyloid beta oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis. Acta Neuropathol129, 183–206.
36.
BenilovaI, KarranE, De StrooperB (2012) The toxic Abeta oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat Neurosci15, 349–357.
37.
BrodyDL, JiangH, WildburgerN, EsparzaTJ (2017) Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer’s disease. Alzheimers Res Ther9, 62.
38.
MurakamiK (2014) Conformation-specific antibodies to target amyloid beta oligomers and their application to immunotherapy for Alzheimer’s disease. Biosci Biotechnol Biochem78, 1293–1305.
NakanishiH (2003) Neuronal and microglial cathepsins in aging and age-related diseases. Ageing Res Rev2, 367–381.
41.
CermakS, KosicekM, Mladenovic-DjordjevicA, Smil-janicK, KanazirS, HecimovicS (2016) Loss of cathepsin B and L leads to lysosomal dysfunction, NPC-like cholesterol sequestration and accumulation of the key Alzheimer’s proteins. PLoS One11, e0167428.
42.
CataldoAM, NixonRA (1990) Enzymatically active lyso-somal proteases are associated with amyloid deposits in Alzheimer brain. Proc Natl Acad Sci USA87, 3861–3865.
43.
IshidohK, KominamiE (2002) Processing and activation of lysosomal proteinases. Biol Chem383, 1827–1831.
44.
MachL, MortJS, GlosslJ (1994) Maturation of human procathepsin B. Proenzyme activation and proteolytic processing of the precursor to the mature proteinase, in vitro, are primarily unimolecular processes. J Biol Chem269, 13030–13035.
45.
RobertsR (2005) Lysosomal cysteine proteases: structure, function and inhibition of cathepsins. Drug News Perspect18, 605–614.
46.
ButtleDJ, MurataM, KnightCG, BarrettAJ (1992) CA074 methyl ester: a proinhibitor for intracellular cathepsin B. Arch Biochem Biophys299, 377–380.
47.
SantanaS, SastreI, RecueroM, BullidoMJ, AldudoJ (2013) Oxidative stress enhances neurodegeneration markers induced by herpes simplex virus type 1 infection in human neuroblastoma cells. PLoS One8, e75842.
48.
TamboK, YamaguchiT, KobayashiK, TerauchiE, IchiI, KojoS (2013) Racemization of the aspartic acid residue of amyloid-beta peptide by a radical reaction. Biosci Biotechnol Biochem77, 416–418.
49.
InoueK, HosakaD, MochizukiN, AkatsuH, TsutsumiuchiK, HashizumeY, MatsukawaN, YamamotoT, Toyo'okaT (2014) Simultaneous determination of post-translational racemization and isomerization of N-terminal amyloid beta in Alzheimer’s brain tissues by covalent chiral deriva-tized ultraperformance liquid chromatography tandem mass spectrometry. Anal Chem86,797–804.
50.
CheignonC, TomasM, Bonnefont-RousselotD, FallerP, HureauC, CollinF (2018) Oxidative stress and the amyloid beta peptide in Alzheimer’s disease. Redox Biol14, 450–464.
51.
ClineEN, BiccaMA, ViolaKL, KleinWL (2018) The amyloid-β oligomer hypothesis: beginning of the third decade. J Alzheimers Dis64, S567–S610.
52.
WhyteLS, LauAA, HemsleyKM, HopwoodJJ, SargeantTJ (2017) Endo-lysosomal and autophagic dysfunction: a driving factor in Alzheimer’s disease?J Neurochem140, 703–717.
53.
CataldoAM, PetanceskaS, TerioNB, PeterhoffCM, DurhamR, MerckenM, MehtaPD, BuxbaumJ, Haroutu-nianV, NixonRA (2004) Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. Neurobiol Aging25, 1263–1272.
54.
TaneoJ, AdachiT, YoshidaA, TakayasuK, TakaharaK, InabaK (2015) Amyloid beta oligomers induce interleukin-lbeta production in primary microglia in a cathepsin Band reactive oxygen species-dependent manner. Biochem Biophys Res Commun458, 561–567.
55.
ChoK, YoonSY, ChoiJE, KangHJ, JangHY, KimDH (2013) CA-074Me, a cathepsin B inhibitor, decreases APP accumulation and protects primary rat cortical neurons treated with okadaic acid. Neurosci Lett548, 222–227.
